Seroatlas · Human Serome Atlas

GHRH

Somatoliberin

Also known as: GHRF, SLIB_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: P01286
Gene: GHRH
Ensembl: ENSG00000118702
Chromosome: 20
Canonical length: 108 aa
Protein class: Human disease related genes, Predicted secreted proteins
Secretome location: Secreted in other tissues

OverviewNCBI Gene

This gene encodes a member of the glucagon family of proteins. The encoded preproprotein is produced in the hypothalamus and cleaved to generate the mature factor, known as somatoliberin, which acts to stimulate growth hormone release from the pituitary gland. Variant receptors for somatoliberin have been found in several types of tumors, and antagonists of these receptors can inhibit the growth of the tumors. Defects in this gene are a cause of dwarfism, while hypersecretion of the encoded protein is a cause of gigantism. Alternative splicing results in multiple transcript variants, at least one of which encodes a preproprotein that is proteolytically processed. [provided by RefSeq, Jan 2016]

Canonical amino-acid sequenceUniProt

108 residues, UniProt reviewed canonical sequence.

>P01286|GHRH
     1  MPLWVFFFVI LTLSNSSHCS PPPPLTLRMR RYADAIFTNS YRKVLGQLSA RKLLQDIMSR
    61  QQGESNQERG ARARLGRQVD SMWAEQKQME LESILVALLQ KHSRNSQG

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against GHRH can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Secreted
Secreted: Yes
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.55
Highest tissue expression: 64 nTPM

Expression across tissuesHPA

Tissue

hypothalamus: 64 nTPM
heart muscle: 12 nTPM
thymus: 8.4 nTPM
duodenum: 2.9 nTPM
small intestine: 1.2 nTPM
adrenal gland: 0.6 nTPM

Single-cell type

other brain neurons: 11 nCPM
epicardial cells: 2.3 nCPM
breast hormone-responsive cells: 1 nCPM
late spermatids: 0.7 nCPM
neuroendocrine cells: 0.7 nCPM
salivary ionocytes: 0.7 nCPM

Immune cell

eosinophil: 0.3 nTPM
myeloid DC: 0.1 nTPM
basophil: 0 nTPM
classical monocyte: 0 nTPM
gdT-cell: 0 nTPM
intermediate monocyte: 0 nTPM

Brain region

hypothalamus: 429 nTPM
basal ganglia: 0.7 nTPM
white matter: 0.6 nTPM
cerebral cortex: 0.5 nTPM
midbrain: 0.5 nTPM
thalamus: 0.5 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.06
gnomAD pLI: 0.15
gnomAD missense Z: 0.38
DepMap mean gene effect: 0.06
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 2% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

growth hormone-releasing hormone activity
neuropeptide hormone activity
peptide hormone receptor binding
growth hormone-releasing hormone receptor binding

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads GHRH as an antibody target. Whether an autoantibody or antibody against GHRH could matter depends on whether native GHRH is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

GHRH is annotated as secreted, so native GHRH circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.

Annotation status

The present source text does not explicitly label GHRH as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...